Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

117
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
117
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.2K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.2K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.2K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.2K
Decreased Body Temperature01:29

Decreased Body Temperature

900
A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...
900
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

592
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
592
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

191
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
191

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.

Antioxidants (Basel, Switzerland)·2026
Same author

Quantitative Assessment of GFAP-Based Astrocyte Morphology in the Cuprizone Model: A Comparative Evaluation of Neurolucida<sup>®</sup> 360 and SNT.

Cells·2026
Same author

Before synapses are lost: Do endogenous retroviruses drive microglial overpruning in autism spectrum disorders?

Neuron·2026
Same author

Astrocytic Accumulation at the Choroid Plexus Attachment Region.

Cellular and molecular neurobiology·2026
Same author

THC and CBD Induce Heme Oxygenase-1-Dependent Cell Death and Trigger Mitochondrial Dysfunction in Human Melanoma and Cutaneous Squamous Cell Carcinoma Cells.

Antioxidants (Basel, Switzerland)·2026
Same author

Dominant clones leverage developmental epigenomic states to drive ependymoma.

Nature·2026
Same journal

RETRACTED: Bakshi et al. Crocin Inhibits Angiogenesis and Metastasis in Colon Cancer via TNF-α/NF-kB/VEGF Pathways. <i>Cells</i> 2022, <i>11</i>, 1502.

Cells·2026
Same journal

Correction: Verde et al. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. <i>Cells</i> 2025, <i>14</i>, 680.

Cells·2026
Same journal

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype.

Cells·2026
Same journal

IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.

Cells·2026
Same journal

Activity of DNA- and RNA-Guided Prokaryotic Argonautes in Human Mitochondria.

Cells·2026
Same journal

Placental Pathophysiology in Maternal Psychoactive Substance Use: Biological, Clinical, and Forensic Perspectives.

Cells·2026
See all related articles

Related Experiment Video

Updated: Dec 25, 2025

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.2K

The Cuprizone Model: Dos and Do Nots.

Jiangshan Zhan1, Teresa Mann1, Sarah Joost1

  • 1Institute of Anatomy, Rostock University Medical Center, Gertrudenstrasse 9, 18057 Rostock, Germany.

Cells
|April 5, 2020
PubMed
Summary
This summary is machine-generated.

The cuprizone model offers valuable insights into multiple sclerosis (MS) pathology. This guide details its use and potential pitfalls for researchers studying this central nervous system disease.

Keywords:
cuprizone modelhistological analysesmultiple sclerosis

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.0K

Related Experiment Videos

Last Updated: Dec 25, 2025

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.2K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.0K

Area of Science:

  • Neuroscience
  • Immunology
  • Toxicology

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease affecting the central nervous system.
  • Pre-clinical models are crucial for understanding MS pathogenesis and developing therapies.
  • The cuprizone model has gained popularity for studying specific aspects of MS pathology.

Purpose of the Study:

  • To provide a practical guide for utilizing the cuprizone model in MS research.
  • To highlight potential pitfalls and challenges associated with the cuprizone model.
  • To aid researchers in effectively applying this model for therapeutic development.

Main Methods:

  • Administration of cuprizone to induce toxic demyelination in animal models.
  • Monitoring of demyelination and remyelination processes.
  • Assessment of inflammatory and cellular responses within the central nervous system.

Main Results:

  • The cuprizone model effectively replicates key pathological features of MS, including demyelination.
  • Specific protocols allow for the study of distinct phases of MS-like pathology.
  • Understanding model limitations is essential for accurate interpretation of results.

Conclusions:

  • The cuprizone model is a powerful tool for investigating MS pathogenesis.
  • Careful application and awareness of pitfalls enhance the model's utility.
  • This model significantly contributes to the development of novel therapeutic strategies for MS.